LMRI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lumexa Imaging Holdings Inc (LMRI) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock lacks immediate positive catalysts, has no significant trading signals, and is currently experiencing a pre-market decline. While the company's financial performance shows improvement in key metrics, its negative net income and lack of recent influential trading activity suggest a cautious approach. Analysts have lowered price targets, and the stock's technical indicators are neutral, providing no clear entry signal.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 47.727, and moving averages are converging, showing no clear trend. The stock is trading near its support level of 8.97, with resistance at 10.139. Overall, the technical indicators suggest a neutral trend with no strong buy signal.
EPS improved significantly by 46.15% YoY, and gross margin increased by 134.18%. Analysts note the company's superior external growth strategy and joint venture mix.
Pre-market price is down 2.98%. Analysts have lowered price targets recently, citing soft Q1 outlook and communication issues. The company still has negative net income and EPS. No recent news or significant trading activity from hedge funds, insiders, or Congress.
In Q4 2025, revenue increased to $267.73M (up 7.95% YoY), net income improved but remained negative at -$28.69M (up 14.49% YoY), EPS increased to -0.38 (up 46.15% YoY), and gross margin rose to 11.1% (up 134.18% YoY).
Barclays and Raymond James recently lowered price targets to $15 and $17, respectively, citing concerns over cash flow, adjusted EBITDA, and communication issues. However, Raymond James maintains a Strong Buy rating due to valuation and growth strategy.
